Approximately 250 delegates from 25 different countries attended the 14th conference in this series held at the Omni Shoreham Hotel in Washington DC, March 21-23, 2016. Over the three days of the conference, 45 oral presentations were given divide over 11 plenary sessions. A Special Symposium on March 21 provided four additional presentations by industry on some of their ongoing oncology drug development programs.
Twenty-three unique new drugs or drug classes, which were in early-phase clinical studies at the time of the conference, were presented, including many studies conducted by globally leading oncology phase 1 groups. Most of the drugs presented had already shown signs of clinical activity in cancer patients. Thus, the conference provided a glimpse of the future of systemic cancer therapy and the new agents that may expand the therapeutic armamentarium in a few years’ time.
Definite highlights were the TAT 2016 Honorary Award Lecture by Dr. Anthony Tolcher under the title “Disrupting Early Clinical Trials”, a Keynote Lecture by Dr. Laurence Zitvogel on “Rational Combinations of Immunological, Targeted and Chemotherapeutic Agents”, and another Keynote Lecture by Dr. Matthew Meyerson on “Genomic Analysis and Targeted Therapy of Lung Cancers”. Immuno-oncology was one of the main themes of the program, with presentations about biomarkers for checkpoint inhibitors, tumor genomics and immunotherapy, and the use of modified T cells in cancer therapy.
The program was supplemented by over 30 posters, which provided data on possible new drugs and drug targets. Abstracts of most presentations are available for downloading from this website and will be published in Frontiers in Oncology in April 2016. Many presentations may be viewed on this website soon.